Nasdaq

New vial options deliver on CSL Behring's heritage of innovation by providing more alternatives to patients

KING OF PRUSSIA, Pa., April 25, 2019 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the US Food and Drug Administration (FDA) has approved 4- and 5-gram vial sizes for ...
irblog.prnewswire.com

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD)

KING OF PRUSSIA, Pa., June 1, 2015 /PRNewswire/ -- Findings from CSL Behring's RAPID study, the largest placebo-controlled trial ever conducted in patients with alpha-1 antitrypsin deficiency (AATD), ...
Nasdaq

CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-Gram Vials

- 4- and 5-gram ZEMAIRA® vials may reduce the number of vials necessary for reconstitution, thereby providing convenience and lowering package waste KING OF PRUSSIA, Pa., Jan. 2, 2024 /PRNewswire/ -- ...
Monthly Prescribing Reference

Drug Shortage and Manufacturing Delays for Zemaira

Zemaira is indicated for chronic augmentation and maintenance therapy in adults with alpha1-proteinase inhibitor deficiency and clinical evidence of emphysema. CSL Behring LLC has informed the Food ...
irblog.prnewswire.com

New vial options deliver on CSL Behring's heritage of innovation by providing more alternatives to patients

ZEMAIRA dosing is weight-based, so a patient weighing 184 pounds currently requires five 1-gram vials. With the larger vial sizes, a majority of patients will be able to streamline their preparation ...